Cyclerion Therapeutics, Inc. announced that in connection with the Separation, William Huyett and Gina Consylman resigned from their positions as members of the Company's board of directors. Effective upon the completion of the Separation, the Board increased the size of the Board from three to nine directors and appointed the following individuals to fill the resulting vacancies and to serve on the committees of the Board are: Peter M. Hecht, Kevin Churchwell, Marsha Fanucci, Ole Isacson, Stephanie Lovell, Terrance McGuire, Michael Mendelsohn and Amy Schulman. Ms. Fanucci, who prior to the Separation was, and remains, a member of the Board, stepped down from the Audit Committee and was appointed to the Nominating and Corporate Governance Committee upon the completion of the Separation.

In connection with the Separation following individuals were elected to the positions as Peter M. Hecht as Chief Executive Officer, Mark G. Currie as President and William Huyett as Chief Financial Officer.